Topical Analgesic Patches: Lidocaine vs Salonpas vs Capsaicin
For neuropathic pain, use lidocaine 5% patches as first-line therapy for postherpetic neuralgia and consider capsaicin 8% patches for more severe or refractory peripheral neuropathic pain; for musculoskeletal pain, Salonpas (menthol/methyl salicylate) patches are appropriate for mild-to-moderate pain but lack the evidence base of the other options.
Indications & Evidence Hierarchy
Lidocaine 5% Patches
Strongest evidence for neuropathic pain conditions, particularly postherpetic neuralgia where it has FDA approval 1. The evidence supports efficacy in:
- Postherpetic neuralgia (FDA-approved, strong evidence) 2, 3
- Diabetic peripheral neuropathy (moderate evidence, off-label) 4
- HIV-associated peripheral neuropathy (can be used as adjunct) 5
- Localized neuropathic pain with allodynia 2
The 2023 Mayo Clinic guideline specifically recommends lidocaine patches for erythromelalgia pain, noting they can be worn 12-24 hours and are "particularly practical for use on the dorsal or plantar surface of the feet" 6. A case series showed most patients improved with 5% patches after failing lidocaine gel 6.
Capsaicin 8% Patches
Strongest evidence for severe peripheral neuropathic pain with high-quality data 5:
- HIV-associated peripheral neuropathy (strong recommendation, high-quality evidence) 5
- Postherpetic neuralgia (strong evidence) 3, 4
- Diabetic peripheral neuropathy (strong evidence) 4
The 2017 HIV/IDSA guideline gives capsaicin 8% a strong recommendation with high-quality evidence, noting "a single 30-minute application can provide pain relief for at least 12 weeks" 5. The 2025 Lancet meta-analysis calculated NNT=13.2 with NNH=1129.3 (moderate certainty) 3.
Critical caveat: Erythema and pain are common during application; pretreat with 4% lidocaine for 60 minutes before applying capsaicin 5.
Salonpas Patches (Menthol 3%/Methyl Salicylate 10%)
FDA-approved for mild-to-moderate musculoskeletal pain 7:
- Sore muscles, sprains, backache, joint pain
- Apply for 8-12 hours
- Do not use more than one patch at a time (FDA label warning)
No guideline-level evidence for neuropathic pain. This is a counterirritant/rubefacient mechanism, fundamentally different from lidocaine's sodium channel blockade or capsaicin's TRPV1 receptor defunctionalization 8.
Dosing & Administration
Lidocaine 5% Patches
- Up to 3-4 patches per 24 hours (safe systemic levels documented) 1
- Apply for 12 hours on, 12 hours off (standard) or up to 24 hours continuously 6
- Available OTC at 4% or prescription 5% strength 6
- The newer 1.8% lidocaine system is bioequivalent to 5% but with superior adhesion 9
Capsaicin 8% Patches
- Single 30-60 minute application by trained healthcare provider 5
- Pretreat with lidocaine 4% for 60 minutes, wipe off before capsaicin application 5
- Duration of effect: up to 12 weeks 5
- Can repeat if first application fails—in one study, 6 of 8 non-responders improved 50% after second patch 10
- 54-58% of patients experience burning sensations (moderate-to-high intensity, lasting ~2 days) 10
Salonpas Patches
- One patch for 8-12 hours 7
- Maximum one patch at a time (FDA label)
- For temporary relief only
Safety Profile
Lidocaine 5% Patches
Excellent safety profile with minimal systemic absorption 1:
- Adverse effects: mild local skin reactions, rare rash
- No drug-drug interactions 1
- Contraindication: advanced liver failure (decreased lidocaine clearance) 1
- Particularly advantageous in older adults and patients with polypharmacy 11
Capsaicin 8% Patches
- Common: erythema, burning pain at application site (54-58% of patients) 10
- Duration of burning: typically 2 days, moderate-to-high intensity 10
- Minimal systemic absorption when properly applied 8
- Requires healthcare provider administration
Salonpas Patches
- Generally well-tolerated for short-term use
- Salicylate absorption possible—caution with aspirin allergy or anticoagulation
- Not studied for long-term use
Clinical Decision Algorithm
For neuropathic pain:
- First-line: Lidocaine 5% patches for localized neuropathic pain, especially postherpetic neuralgia or diabetic neuropathy with allodynia 3, 4
- Second-line or severe cases: Capsaicin 8% patches for more severe or refractory peripheral neuropathic pain (HIV neuropathy, postherpetic neuralgia, diabetic neuropathy) 5, 3
- Trial lidocaine for at least 4 weeks before switching 6
For musculoskeletal pain:
- Salonpas patches appropriate for mild-to-moderate acute musculoskeletal pain (sprains, muscle soreness)
- Consider topical NSAIDs (diclofenac gel/patch) for osteoarthritis instead—stronger evidence base 12
Key distinction: The 2025 Lancet meta-analysis shows lidocaine has NNT=14.5 (very low certainty) while capsaicin 8% has NNT=13.2 (moderate certainty) for neuropathic pain 3. However, lidocaine's superior safety profile and ease of use justify first-line positioning for most patients, reserving capsaicin 8% for inadequate responders or severe cases.
Common Pitfalls
- Don't use Salonpas for neuropathic pain—no evidence base; mechanism is counterirritant, not neuropathic pain-specific
- Don't apply capsaicin 8% without lidocaine pretreatment—significantly increases tolerability 5
- Don't exceed one Salonpas patch at a time (FDA warning) but can use up to 4 lidocaine patches safely 1
- Don't expect immediate results with lidocaine—trial for 4 weeks minimum 6
- Don't dismiss capsaicin 8% after first failure—consider second application 10
- Lidocaine patches are not for wound care despite off-label use 1